<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2010-09-14" updated="2020-01-02">
  <drugbank-id primary="true">DB06781</drugbank-id>
  <name>Difluprednate</name>
  <description>Difluprednate is a topical corticosteroid indicated for the treatment of infammation and pain associated with ocular surgery. It is a butyrate ester of 6(α), 9(α)-difluoro prednisolone acetate. Difluprednate is abbreviated DFBA, or difluoroprednisolone butyrate acetate. It is indicated for treatment of endogenous anterior uveiti.</description>
  <cas-number>23674-86-4</cas-number>
  <unii>S8A06QG2QE</unii>
  <average-mass>508.5515</average-mass>
  <monoisotopic-mass>508.227259852</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A7076</ref-id>
        <pubmed-id>19101421</pubmed-id>
        <citation>Korenfeld MS, Silverstein SM, Cooke DL, Vogel R, Crockett RS: Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. J Cataract Refract Surg. 2009 Jan;35(1):26-34. doi: 10.1016/j.jcrs.2008.09.024.</citation>
      </article>
      <article>
        <ref-id>A7077</ref-id>
        <pubmed-id>19668594</pubmed-id>
        <citation>Jamal KN, Callanan DG: The role of difluprednate ophthalmic emulsion in clinical practice. Clin Ophthalmol. 2009;3:381-90. Epub 2009 Jun 29.</citation>
      </article>
      <article>
        <ref-id>A7078</ref-id>
        <pubmed-id>2666872</pubmed-id>
        <citation>Morton KD, Van de Kar LD, Brownfield MS, Bethea CL: Neuronal cell bodies in the hypothalamic paraventricular nucleus mediate stress-induced renin and corticosterone secretion. Neuroendocrinology. 1989 Jul;50(1):73-80.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Ercoli, A. and Gardi, R.; U.S. Patent 3,780,177; December 18,1973; assigned to Warner-Lambert Co.</synthesis-reference>
  <indication>For the treatment of inflammation and pain associated with ocular surgery.</indication>
  <pharmacodynamics>Difluprednate is a corticosteroid used as an anti-inflammatory steroidal drug used primarily in ocular surgery.</pharmacodynamics>
  <mechanism-of-action>Corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins (lipocortins). It is postulated that these proteins control the biosynthesis of potent mediators of infammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.</mechanism-of-action>
  <toxicity>Preclinical pharmacokinetic and toxicity studies have established that difluprednate ophthalmic emulsion 0.05% given 4 times a day is not toxic to the eye.</toxicity>
  <metabolism>Difluprednate is rapidly deacetylated in the aqueous humor to difluoroprednisolone butyrate (DFB), the drug’s active metabolite. Endogenous tissue esterases then metabolize DFB to the inert metabolite hydroxyfluoroprednisolone butyrate (HFB), which limits systemic exposure to the active compound.</metabolism>
  <absorption>Difluprednate penetrates the corneal epithelium rapidly and effectively. Low systemic absorption. </absorption>
  <half-life/>
  <protein-binding/>
  <route-of-elimination>78.5% of radioactivity was excreted aftert 24 hours, and 99.5% by 7 days after a single dose of labeled difluprednate instilled in the right eyes of pigmented rabbits.</route-of-elimination>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.</description>
    <direct-parent>Gluco/mineralocorticoids, progestogins and derivatives</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Lipids and lipid-like molecules</superclass>
    <class>Steroids and steroid derivatives</class>
    <subclass>Pregnane steroids</subclass>
    <alternative-parent>11-beta-hydroxysteroids</alternative-parent>
    <alternative-parent>20-oxosteroids</alternative-parent>
    <alternative-parent>3-oxo delta-1,4-steroids</alternative-parent>
    <alternative-parent>Alkyl fluorides</alternative-parent>
    <alternative-parent>Alpha-acyloxy ketones</alternative-parent>
    <alternative-parent>Carboxylic acid esters</alternative-parent>
    <alternative-parent>Cyclic alcohols and derivatives</alternative-parent>
    <alternative-parent>Cyclic ketones</alternative-parent>
    <alternative-parent>Delta-1,4-steroids</alternative-parent>
    <alternative-parent>Dicarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Fluorohydrins</alternative-parent>
    <alternative-parent>Halogenated steroids</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organofluorides</alternative-parent>
    <alternative-parent>Secondary alcohols</alternative-parent>
    <alternative-parent>Steroid esters</alternative-parent>
    <substituent>11-beta-hydroxysteroid</substituent>
    <substituent>11-hydroxysteroid</substituent>
    <substituent>20-oxosteroid</substituent>
    <substituent>3-oxo-delta-1,4-steroid</substituent>
    <substituent>3-oxosteroid</substituent>
    <substituent>6-halo-steroid</substituent>
    <substituent>9-halo-steroid</substituent>
    <substituent>Alcohol</substituent>
    <substituent>Aliphatic homopolycyclic compound</substituent>
    <substituent>Alkyl fluoride</substituent>
    <substituent>Alkyl halide</substituent>
    <substituent>Alpha-acyloxy ketone</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Carboxylic acid ester</substituent>
    <substituent>Cyclic alcohol</substituent>
    <substituent>Cyclic ketone</substituent>
    <substituent>Delta-1,4-steroid</substituent>
    <substituent>Dicarboxylic acid or derivatives</substituent>
    <substituent>Fluorohydrin</substituent>
    <substituent>Halo-steroid</substituent>
    <substituent>Halohydrin</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Hydroxysteroid</substituent>
    <substituent>Ketone</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organofluoride</substituent>
    <substituent>Organohalogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Oxosteroid</substituent>
    <substituent>Progestogin-skeleton</substituent>
    <substituent>Secondary alcohol</substituent>
    <substituent>Steroid ester</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">DFBA</synonym>
    <synonym language="english" coder="">Difluoroprednisolone butyrate acetate</synonym>
    <synonym language="english" coder="inn/usan">Difluprednate</synonym>
  </synonyms>
  <products>
    <product>
      <name>Durezol</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02415534</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-02-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Emulsion</dosage-form>
      <strength>0.05 %</strength>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Durezol</name>
      <labeller>ALCON LABORATORIES, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>0065-9240</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Emulsion</dosage-form>
      <strength>0.5 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>NDA022212</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Durezol</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6296</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Emulsion</dosage-form>
      <strength>0.5 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>NDA022212</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Durezol</name>
      <labeller>Sirion Therapeutics, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42826-601</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-09-01</started-marketing-on>
      <ended-marketing-on>2010-06-24</ended-marketing-on>
      <dosage-form>Emulsion</dosage-form>
      <strength>0.5 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>NDA022212</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Durezol</name>
      <ingredients>Difluprednate</ingredients>
    </mixture>
    <mixture>
      <name>Durezol</name>
      <ingredients>Difluprednate</ingredients>
    </mixture>
    <mixture>
      <name>Durezol</name>
      <ingredients>Difluprednate</ingredients>
    </mixture>
    <mixture>
      <name>Durezol</name>
      <ingredients>Difluprednate</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Adrenal Cortex Hormones</category>
      <mesh-id>D000305</mesh-id>
    </category>
    <category>
      <category>Corticosteroids</category>
      <mesh-id>D000305</mesh-id>
    </category>
    <category>
      <category>Corticosteroids, Dermatological Preparations</category>
      <mesh-id/>
    </category>
    <category>
      <category>Corticosteroids, Potent (Group III)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A4 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Dermatologicals</category>
      <mesh-id>D003879</mesh-id>
    </category>
    <category>
      <category>Fused-Ring Compounds</category>
      <mesh-id>D000072473</mesh-id>
    </category>
    <category>
      <category>Hormones</category>
      <mesh-id>D006728</mesh-id>
    </category>
    <category>
      <category>Hormones, Hormone Substitutes, and Hormone Antagonists</category>
      <mesh-id>D006730</mesh-id>
    </category>
    <category>
      <category>Immunosuppressive Agents</category>
      <mesh-id>D007166</mesh-id>
    </category>
    <category>
      <category>Pregnadienes</category>
      <mesh-id>D011245</mesh-id>
    </category>
    <category>
      <category>Pregnadienetriols</category>
      <mesh-id>D011246</mesh-id>
    </category>
    <category>
      <category>Pregnanes</category>
      <mesh-id>D011278</mesh-id>
    </category>
    <category>
      <category>Steroids</category>
      <mesh-id>D013256</mesh-id>
    </category>
    <category>
      <category>Steroids, Fluorinated</category>
      <mesh-id>D013259</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Emulsion</form>
      <route>Ophthalmic</route>
      <strength>0.05 %</strength>
    </dosage>
    <dosage>
      <form>Emulsion</form>
      <route>Ophthalmic</route>
      <strength>0.5 mg/1mL</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="D07AC19">
      <level code="D07AC">Corticosteroids, potent (group III)</level>
      <level code="D07A">CORTICOSTEROIDS, PLAIN</level>
      <level code="D07">CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS</level>
      <level code="D">DERMATOLOGICALS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>52:08.08</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB06781.pdf?1284753084</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB06781.pdf?1363637163</msds>
  <patents>
    <patent>
      <number>6114319</number>
      <country>United States</country>
      <approved>2000-09-05</approved>
      <expires>2019-11-18</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00072</drugbank-id>
      <name>Trastuzumab</name>
      <description>Trastuzumab may increase the neutropenic activities of Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>Tacrolimus may increase the immunosuppressive activities of Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01432</drugbank-id>
      <name>Cholestyramine</name>
      <description>Cholestyramine may increase the excretion rate of Difluprednate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00180</drugbank-id>
      <name>Flunisolide</name>
      <description>The risk or severity of hypertension can be increased when Flunisolide is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00223</drugbank-id>
      <name>Diflorasone</name>
      <description>The risk or severity of hypertension can be increased when Diflorasone is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00240</drugbank-id>
      <name>Alclometasone</name>
      <description>The risk or severity of hypertension can be increased when Alclometasone is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00253</drugbank-id>
      <name>Medrysone</name>
      <description>The risk or severity of hypertension can be increased when Medrysone is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00288</drugbank-id>
      <name>Amcinonide</name>
      <description>The risk or severity of hypertension can be increased when Amcinonide is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00324</drugbank-id>
      <name>Fluorometholone</name>
      <description>The risk or severity of hypertension can be increased when Fluorometholone is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00394</drugbank-id>
      <name>Beclomethasone dipropionate</name>
      <description>The risk or severity of hypertension can be increased when Beclomethasone dipropionate is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The risk or severity of hypertension can be increased when Betamethasone is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00547</drugbank-id>
      <name>Desoximetasone</name>
      <description>The risk or severity of hypertension can be increased when Desoximetasone is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>The risk or severity of hypertension can be increased when Fluticasone propionate is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00591</drugbank-id>
      <name>Fluocinolone acetonide</name>
      <description>The risk or severity of hypertension can be increased when Fluocinolone acetonide is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00596</drugbank-id>
      <name>Ulobetasol</name>
      <description>The risk or severity of hypertension can be increased when Ulobetasol is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00620</drugbank-id>
      <name>Triamcinolone</name>
      <description>The risk or severity of hypertension can be increased when Triamcinolone is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The risk or severity of hypertension can be increased when Prednisone is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00663</drugbank-id>
      <name>Flumethasone</name>
      <description>The risk or severity of hypertension can be increased when Flumethasone is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00687</drugbank-id>
      <name>Fludrocortisone</name>
      <description>The risk or severity of hypertension can be increased when Fludrocortisone is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>The risk or severity of hypertension can be increased when Hydrocortisone is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00764</drugbank-id>
      <name>Mometasone</name>
      <description>The risk or severity of hypertension can be increased when Mometasone is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00838</drugbank-id>
      <name>Clocortolone</name>
      <description>The risk or severity of hypertension can be increased when Clocortolone is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00846</drugbank-id>
      <name>Flurandrenolide</name>
      <description>The risk or severity of hypertension can be increased when Flurandrenolide is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The risk or severity of hypertension can be increased when Prednisolone is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14596</drugbank-id>
      <name>Loteprednol etabonate</name>
      <description>The risk or severity of hypertension can be increased when Loteprednol etabonate is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00896</drugbank-id>
      <name>Rimexolone</name>
      <description>The risk or severity of hypertension can be increased when Rimexolone is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The risk or severity of hypertension can be increased when Methylprednisolone is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01013</drugbank-id>
      <name>Clobetasol propionate</name>
      <description>The risk or severity of hypertension can be increased when Clobetasol propionate is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01047</drugbank-id>
      <name>Fluocinonide</name>
      <description>The risk or severity of hypertension can be increased when Fluocinonide is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01108</drugbank-id>
      <name>Trilostane</name>
      <description>The risk or severity of hypertension can be increased when Trilostane is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01130</drugbank-id>
      <name>Prednicarbate</name>
      <description>The risk or severity of hypertension can be increased when Prednicarbate is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>The risk or severity of hypertension can be increased when Budesonide is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The risk or severity of hypertension can be increased when Dexamethasone is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01260</drugbank-id>
      <name>Desonide</name>
      <description>The risk or severity of hypertension can be increased when Desonide is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01285</drugbank-id>
      <name>Corticotropin</name>
      <description>The risk or severity of hypertension can be increased when Corticotropin is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01380</drugbank-id>
      <name>Cortisone acetate</name>
      <description>The risk or severity of hypertension can be increased when Cortisone acetate is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01384</drugbank-id>
      <name>Paramethasone</name>
      <description>The risk or severity of hypertension can be increased when Paramethasone is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01410</drugbank-id>
      <name>Ciclesonide</name>
      <description>The risk or severity of hypertension can be increased when Ciclesonide is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04630</drugbank-id>
      <name>Aldosterone</name>
      <description>The risk or severity of hypertension can be increased when Aldosterone is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06786</drugbank-id>
      <name>Halcinonide</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Halcinonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08906</drugbank-id>
      <name>Fluticasone furoate</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Fluticasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08970</drugbank-id>
      <name>Fluprednidene</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Fluprednidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08971</drugbank-id>
      <name>Fluocortolone</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Fluocortolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09091</drugbank-id>
      <name>Tixocortol</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Tixocortol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09095</drugbank-id>
      <name>Difluocortolone</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Difluocortolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09378</drugbank-id>
      <name>Fluprednisolone</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Fluprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09383</drugbank-id>
      <name>Meprednisone</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Meprednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11487</drugbank-id>
      <name>Dexamethasone isonicotinate</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Dexamethasone isonicotinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11529</drugbank-id>
      <name>Melengestrol</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Melengestrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11750</drugbank-id>
      <name>Clobetasol</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Clobetasol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11921</drugbank-id>
      <name>Deflazacort</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Deflazacort.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13003</drugbank-id>
      <name>Cortivazol</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Cortivazol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13158</drugbank-id>
      <name>Clobetasone</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Clobetasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13208</drugbank-id>
      <name>Prednylidene</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Prednylidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13223</drugbank-id>
      <name>Fluocortin</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Fluocortin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13491</drugbank-id>
      <name>Fluperolone</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Fluperolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13664</drugbank-id>
      <name>Formocortal</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Formocortal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13728</drugbank-id>
      <name>Halometasone</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Halometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13843</drugbank-id>
      <name>Cloprednol</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Cloprednol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13856</drugbank-id>
      <name>Fluclorolone</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Fluclorolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13867</drugbank-id>
      <name>Fluticasone</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Fluticasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14512</drugbank-id>
      <name>Mometasone furoate</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Mometasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14538</drugbank-id>
      <name>Hydrocortisone aceponate</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Hydrocortisone aceponate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14539</drugbank-id>
      <name>Hydrocortisone acetate</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Hydrocortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14540</drugbank-id>
      <name>Hydrocortisone butyrate</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Hydrocortisone butyrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14541</drugbank-id>
      <name>Hydrocortisone cypionate</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Hydrocortisone cypionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14543</drugbank-id>
      <name>Hydrocortisone probutate</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Hydrocortisone probutate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14544</drugbank-id>
      <name>Hydrocortisone valerate</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Hydrocortisone valerate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14545</drugbank-id>
      <name>Hydrocortisone succinate</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Hydrocortisone succinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00873</drugbank-id>
      <name>Loteprednol</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Loteprednol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14631</drugbank-id>
      <name>Prednisolone phosphate</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Prednisolone phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14633</drugbank-id>
      <name>Prednisolone hemisuccinate</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Prednisolone hemisuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14634</drugbank-id>
      <name>Fluprednidene acetate</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Fluprednidene acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14643</drugbank-id>
      <name>Methylprednisolone aceponate</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Methylprednisolone aceponate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14644</drugbank-id>
      <name>Methylprednisolone hemisuccinate</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Methylprednisolone hemisuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14646</drugbank-id>
      <name>Prednisone acetate</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Prednisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14652</drugbank-id>
      <name>Clocortolone acetate</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Clocortolone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14659</drugbank-id>
      <name>Melengestrol acetate</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Melengestrol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14669</drugbank-id>
      <name>Betamethasone phosphate</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Betamethasone phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14681</drugbank-id>
      <name>Cortisone</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Cortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15566</drugbank-id>
      <name>Prednisolone acetate</name>
      <description>The risk or severity of hypertension can be increased when Difluprednate is combined with Prednisolone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00357</drugbank-id>
      <name>Aminoglutethimide</name>
      <description>The therapeutic efficacy of Difluprednate can be decreased when used in combination with Aminoglutethimide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00951</drugbank-id>
      <name>Isoniazid</name>
      <description>The serum concentration of Isoniazid can be decreased when it is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>The risk or severity of adverse effects can be increased when Difluprednate is combined with Cyclosporine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>The risk or severity of adverse effects can be increased when Difluprednate is combined with Digoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00511</drugbank-id>
      <name>Acetyldigitoxin</name>
      <description>The risk or severity of adverse effects can be increased when Difluprednate is combined with Acetyldigitoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01078</drugbank-id>
      <name>Deslanoside</name>
      <description>The risk or severity of adverse effects can be increased when Difluprednate is combined with Deslanoside.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01396</drugbank-id>
      <name>Digitoxin</name>
      <description>The risk or severity of adverse effects can be increased when Difluprednate is combined with Digitoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13401</drugbank-id>
      <name>Metildigoxin</name>
      <description>The risk or severity of adverse effects can be increased when Difluprednate is combined with Metildigoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13467</drugbank-id>
      <name>Lanatoside C</name>
      <description>The risk or severity of adverse effects can be increased when Difluprednate is combined with Lanatoside C.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13537</drugbank-id>
      <name>Gitoformate</name>
      <description>The risk or severity of adverse effects can be increased when Difluprednate is combined with Gitoformate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13691</drugbank-id>
      <name>Acetyldigoxin</name>
      <description>The risk or severity of adverse effects can be increased when Difluprednate is combined with Acetyldigoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04914</drugbank-id>
      <name>G17DT</name>
      <description>The therapeutic efficacy of G17DT can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05144</drugbank-id>
      <name>PEV3A</name>
      <description>The therapeutic efficacy of PEV3A can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05325</drugbank-id>
      <name>INGN 225</name>
      <description>The therapeutic efficacy of INGN 225 can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05374</drugbank-id>
      <name>Rindopepimut</name>
      <description>The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05440</drugbank-id>
      <name>SRP 299</name>
      <description>The therapeutic efficacy of SRP 299 can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05942</drugbank-id>
      <name>GI-5005</name>
      <description>The therapeutic efficacy of GI-5005 can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06400</drugbank-id>
      <name>Vitespen</name>
      <description>The therapeutic efficacy of Vitespen can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06584</drugbank-id>
      <name>TG4010</name>
      <description>The therapeutic efficacy of TG4010 can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09057</drugbank-id>
      <name>Anthrax immune globulin human</name>
      <description>The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10062</drugbank-id>
      <name>Rabies virus inactivated antigen, B</name>
      <description>The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10076</drugbank-id>
      <name>Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen</name>
      <description>The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10276</drugbank-id>
      <name>Rotavirus vaccine</name>
      <description>The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10283</drugbank-id>
      <name>Rabies virus inactivated antigen, A</name>
      <description>The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10317</drugbank-id>
      <name>Rubella virus vaccine</name>
      <description>The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10318</drugbank-id>
      <name>Varicella Zoster Vaccine (Live/attenuated)</name>
      <description>The therapeutic efficacy of Varicella Zoster Vaccine (Live/attenuated) can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10342</drugbank-id>
      <name>Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen</name>
      <description>The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10343</drugbank-id>
      <name>Bacillus calmette-guerin substrain tice live antigen</name>
      <description>The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10583</drugbank-id>
      <name>Clostridium tetani toxoid antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10584</drugbank-id>
      <name>Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10600</drugbank-id>
      <name>Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10769</drugbank-id>
      <name>Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10794</drugbank-id>
      <name>Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10803</drugbank-id>
      <name>Typhoid Vi polysaccharide vaccine</name>
      <description>The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10804</drugbank-id>
      <name>Bacillus calmette-guerin substrain connaught live antigen</name>
      <description>The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10805</drugbank-id>
      <name>Yellow Fever Vaccine</name>
      <description>The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10989</drugbank-id>
      <name>Hepatitis A Vaccine</name>
      <description>The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10990</drugbank-id>
      <name>Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen</name>
      <description>The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11003</drugbank-id>
      <name>Anthrax vaccine</name>
      <description>The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11038</drugbank-id>
      <name>Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11040</drugbank-id>
      <name>Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11041</drugbank-id>
      <name>Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11044</drugbank-id>
      <name>Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11050</drugbank-id>
      <name>Typhoid Vaccine Live</name>
      <description>The therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11603</drugbank-id>
      <name>Human rabies virus immune globulin</name>
      <description>The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11627</drugbank-id>
      <name>Hepatitis B Vaccine (Recombinant)</name>
      <description>The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12386</drugbank-id>
      <name>Bacillus calmette-guerin substrain danish 1331 live antigen</name>
      <description>The therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12568</drugbank-id>
      <name>Tecemotide</name>
      <description>The therapeutic efficacy of Tecemotide can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12768</drugbank-id>
      <name>BCG vaccine</name>
      <description>The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13924</drugbank-id>
      <name>Varicella Zoster Vaccine (Recombinant)</name>
      <description>The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14022</drugbank-id>
      <name>Typhoid vaccine</name>
      <description>The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14384</drugbank-id>
      <name>Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14385</drugbank-id>
      <name>Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14394</drugbank-id>
      <name>Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen</name>
      <description>The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14409</drugbank-id>
      <name>Human adenovirus e serotype 4 strain cl-68578 antigen</name>
      <description>The therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14443</drugbank-id>
      <name>Vibrio cholerae CVD 103-HgR strain live antigen</name>
      <description>The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14445</drugbank-id>
      <name>Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14449</drugbank-id>
      <name>Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen</name>
      <description>The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14619</drugbank-id>
      <name>Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14620</drugbank-id>
      <name>Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)</name>
      <description>The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14685</drugbank-id>
      <name>Adenovirus type 7 vaccine live</name>
      <description>The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14711</drugbank-id>
      <name>Vaccinia virus strain new york city board of health live antigen</name>
      <description>The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15274</drugbank-id>
      <name>Pertussis vaccine</name>
      <description>The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15461</drugbank-id>
      <name>Yersinia pestis 195/p antigen (formaldehyde inactivated)</name>
      <description>The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15483</drugbank-id>
      <name>Modified vaccinia ankara</name>
      <description>The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01364</drugbank-id>
      <name>Ephedrine</name>
      <description>Ephedrine may increase the excretion rate of Difluprednate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00030</drugbank-id>
      <name>Insulin human</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00046</drugbank-id>
      <name>Insulin lispro</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Insulin lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00047</drugbank-id>
      <name>Insulin glargine</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Insulin glargine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00071</drugbank-id>
      <name>Insulin pork</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00197</drugbank-id>
      <name>Troglitazone</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Troglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00222</drugbank-id>
      <name>Glimepiride</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Glimepiride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00263</drugbank-id>
      <name>Sulfisoxazole</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Sulfisoxazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Disopyramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00284</drugbank-id>
      <name>Acarbose</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Acarbose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00331</drugbank-id>
      <name>Metformin</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Metformin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00359</drugbank-id>
      <name>Sulfadiazine</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Sulfadiazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Rosiglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00414</drugbank-id>
      <name>Acetohexamide</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Acetohexamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Quinine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00491</drugbank-id>
      <name>Miglitol</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Miglitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00672</drugbank-id>
      <name>Chlorpropamide</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Chlorpropamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00731</drugbank-id>
      <name>Nateglinide</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Nateglinide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00738</drugbank-id>
      <name>Pentamidine</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Pentamidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00834</drugbank-id>
      <name>Mifepristone</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Mifepristone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00839</drugbank-id>
      <name>Tolazamide</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Tolazamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00912</drugbank-id>
      <name>Repaglinide</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Repaglinide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00914</drugbank-id>
      <name>Phenformin</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Phenformin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01015</drugbank-id>
      <name>Sulfamethoxazole</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Sulfamethoxazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01016</drugbank-id>
      <name>Glyburide</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Glyburide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01067</drugbank-id>
      <name>Glipizide</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Glipizide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01120</drugbank-id>
      <name>Gliclazide</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Gliclazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01124</drugbank-id>
      <name>Tolbutamide</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Tolbutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01132</drugbank-id>
      <name>Pioglitazone</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Pioglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01200</drugbank-id>
      <name>Bromocriptine</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Bromocriptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01251</drugbank-id>
      <name>Gliquidone</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Gliquidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01252</drugbank-id>
      <name>Mitiglinide</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Mitiglinide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01261</drugbank-id>
      <name>Sitagliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Sitagliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01268</drugbank-id>
      <name>Sunitinib</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Sunitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01276</drugbank-id>
      <name>Exenatide</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Exenatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01277</drugbank-id>
      <name>Mecasermin</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Mecasermin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01278</drugbank-id>
      <name>Pramlintide</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Pramlintide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01289</drugbank-id>
      <name>Glisoxepide</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Glisoxepide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01306</drugbank-id>
      <name>Insulin aspart</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Insulin aspart.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01307</drugbank-id>
      <name>Insulin detemir</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Insulin detemir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01309</drugbank-id>
      <name>Insulin glulisine</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Insulin glulisine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01382</drugbank-id>
      <name>Glymidine</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Glymidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01700</drugbank-id>
      <name>AICA ribonucleotide</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with AICA ribonucleotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04830</drugbank-id>
      <name>Buformin</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Buformin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04876</drugbank-id>
      <name>Vildagliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Vildagliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04878</drugbank-id>
      <name>Voglibose</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Voglibose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05115</drugbank-id>
      <name>NN344</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with NN344.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05819</drugbank-id>
      <name>NBI-6024</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with NBI-6024.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06011</drugbank-id>
      <name>AMG-222</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with AMG-222.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06127</drugbank-id>
      <name>Bisegliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Bisegliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06203</drugbank-id>
      <name>Alogliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Alogliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06292</drugbank-id>
      <name>Dapagliflozin</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Dapagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06335</drugbank-id>
      <name>Saxagliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Saxagliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06655</drugbank-id>
      <name>Liraglutide</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Liraglutide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08382</drugbank-id>
      <name>Gosogliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Gosogliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08882</drugbank-id>
      <name>Linagliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Linagliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08907</drugbank-id>
      <name>Canagliflozin</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Canagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08962</drugbank-id>
      <name>Glibornuride</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Glibornuride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09022</drugbank-id>
      <name>Benfluorex</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Benfluorex.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09038</drugbank-id>
      <name>Empagliflozin</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Empagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09043</drugbank-id>
      <name>Albiglutide</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Albiglutide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09045</drugbank-id>
      <name>Dulaglutide</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Dulaglutide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09198</drugbank-id>
      <name>Lobeglitazone</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Lobeglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09199</drugbank-id>
      <name>Netoglitazone</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Netoglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09200</drugbank-id>
      <name>Rivoglitazone</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Rivoglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09201</drugbank-id>
      <name>Ciglitazone</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Ciglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09265</drugbank-id>
      <name>Lixisenatide</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Lixisenatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09456</drugbank-id>
      <name>Insulin beef</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Insulin beef.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09564</drugbank-id>
      <name>Insulin degludec</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Insulin degludec.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11567</drugbank-id>
      <name>Insulin peglispro</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Insulin peglispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11568</drugbank-id>
      <name>Insulin tregopil</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Insulin tregopil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11698</drugbank-id>
      <name>Ipragliflozin</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Ipragliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11723</drugbank-id>
      <name>Dutogliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Dutogliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11780</drugbank-id>
      <name>Allicin</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Allicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11824</drugbank-id>
      <name>Tofogliflozin</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Tofogliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11827</drugbank-id>
      <name>Ertugliflozin</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Ertugliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11898</drugbank-id>
      <name>2,4-thiazolidinedione</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with 2,4-thiazolidinedione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11936</drugbank-id>
      <name>Bempedoic acid</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Bempedoic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11950</drugbank-id>
      <name>Teneligliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Teneligliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11992</drugbank-id>
      <name>Omarigliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Omarigliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12268</drugbank-id>
      <name>Carmegliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Carmegliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12412</drugbank-id>
      <name>Gemigliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Gemigliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12417</drugbank-id>
      <name>Anagliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Anagliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12625</drugbank-id>
      <name>Evogliptin</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Evogliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12713</drugbank-id>
      <name>Sotagliflozin</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Sotagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12781</drugbank-id>
      <name>Balaglitazone</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Balaglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12935</drugbank-id>
      <name>Remogliflozin etabonate</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Remogliflozin etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13406</drugbank-id>
      <name>Carbutamide</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Carbutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13446</drugbank-id>
      <name>Guar gum</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Guar gum.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13675</drugbank-id>
      <name>Metahexamide</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Metahexamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13928</drugbank-id>
      <name>Semaglutide</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Semaglutide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14027</drugbank-id>
      <name>Taspoglutide</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Taspoglutide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14035</drugbank-id>
      <name>Englitazone</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Englitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15171</drugbank-id>
      <name>Tirzepatide</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Tirzepatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15217</drugbank-id>
      <name>Gastric inhibitory polypeptide</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Gastric inhibitory polypeptide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06119</drugbank-id>
      <name>Cenobamate</name>
      <description>The serum concentration of Difluprednate can be decreased when it is combined with Cenobamate.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>3.28</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4.7</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>9.70e-03 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(1R,2S,8S,10S,11S,14R,15S,17S)-14-[2-(acetyloxy)acetyl]-1,8-difluoro-17-hydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-14-yl butanoate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>difluprednate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>508.5515</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>508.227259852</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C27H34F2O7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C27H34F2O7/c1-5-6-23(34)36-26(22(33)14-35-15(2)30)10-8-17-18-12-20(28)19-11-16(31)7-9-24(19,3)27(18,29)21(32)13-25(17,26)4/h7,9,11,17-18,20-21,32H,5-6,8,10,12-14H2,1-4H3/t17-,18-,20-,21-,24-,25-,26-,27-/m0/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>WYQPLTPSGFELIB-JTQPXKBDSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>106.97</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>125.38</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>51.46</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>8</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>13.55</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-3.4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>191-194</value>
      <source>Ercoli, A. and Gardi, R.; U.S. Patent 3,780,177; December 18,1973; assigned to Warner-Lambert Co.</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>22159</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>31485</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>443936</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>99443292</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C12695</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D01266</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>391990</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA165958405</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Difluprednate</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201749</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/durezol-drug.htm</url>
    </external-link>
    <external-link>
      <resource>PDRhealth</resource>
      <url>http://www.pdrhealth.com/drugs/rx/rx-mono.aspx?contentFileName=dur1999.html&amp;contentName=Durezol&amp;contentId=269</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/durezol.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB06781</drugbank-id>
        <name>Difluprednate</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET00837</drugbank-id>
        <name>difluoroprednisolone butyrate</name>
      </right-element>
      <enzymes/>
    </reaction>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB06781</drugbank-id>
        <name>Difluprednate</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET00883</drugbank-id>
        <name>Hydroxyfluoroprednisolone butyrate (HFB)</name>
      </right-element>
      <enzymes/>
    </reaction>
  </reactions>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000794</id>
      <name>Glucocorticoid receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A7077</ref-id>
            <pubmed-id>19668594</pubmed-id>
            <citation>Jamal KN, Callanan DG: The role of difluprednate ophthalmic emulsion in clinical practice. Clin Ophthalmol. 2009;3:381-90. Epub 2009 Jun 29.</citation>
          </article>
          <article>
            <ref-id>A16915</ref-id>
            <pubmed-id>20509750</pubmed-id>
            <citation>Tajika T, Takahashi H, Sakai Y, Fujii H, Isowaki A, Sakaki H: Metabolic profiles of difluprednate in rabbit ocular tissues after instillation of difluprednate ophthalmic emulsion. Xenobiotica. 2010 Aug;40(8):569-77. doi: 10.3109/00498254.2010.490308.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P04150" source="Swiss-Prot">
        <name>Glucocorticoid receptor</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon growth hormone (GH) stimulation and could reveal an essential role of hepatic GR in the control of body growth. Involved in chromatin remodeling. May play a negative role in adipogenesis through the regulation of lipolytic and antilipogenic genes expression.</specific-function>
        <gene-name>NR3C1</gene-name>
        <locus>5q31.3</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.31</theoretical-pi>
        <molecular-weight>85658.57</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:7978</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>NR3C1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X03225</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>31680</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>625</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>625</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P04150</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>GCR_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>GR</synonym>
          <synonym>GRL</synonym>
          <synonym>Nuclear receptor subfamily 3 group C member 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001584|Glucocorticoid receptor
MDSKESLTPGREENPSSVLAQERGDVMDFYKTLRGGATVKVSASSPSLAVASQSDSKQRR
LLVDFPKGSVSNAQQPDLSKAVSLSMGLYMGETETKVMGNDLGFPQQGQISLSSGETDLK
LLEESIANLNRSTSVPENPKSSASTAVSAAPTEKEFPKTHSDVSSEQQHLKGQTGTNGGN
VKLYTTDQSTFDILQDLEFSSGSPGKETNESPWRSDLLIDENCLLSPLAGEDDSFLLEGN
SNEDCKPLILPDTKPKIKDNGDLVLSSPSNVTLPQVKTEKEDFIELCTPGVIKQEKLGTV
YCQASFPGANIIGNKMSAISVHGVSTSGGQMYHYDMNTASLSQQQDQKPIFNVIPPIPVG
SENWNRCQGSGDDNLTSLGTLNFPGRTVFSNGYSSPSMRPDVSSPPSSSSTATTGPPPKL
CLVCSDEASGCHYGVLTCGSCKVFFKRAVEGQHNYLCAGRNDCIIDKIRRKNCPACRYRK
CLQAGMNLEARKTKKKIKGIQQATTGVSQETSENPGNKTIVPATLPQLTPTLVSLLEVIE
PEVLYAGYDSSVPDSTWRIMTTLNMLGGRQVIAAVKWAKAIPGFRNLHLDDQMTLLQYSW
MFLMAFALGWRSYRQSSANLLCFAPDLIINEQRMTLPCMYDQCKHMLYVSSELHRLQVSY
EEYLCMKTLLLLSSVPKDGLKSQELFDEIRMTYIKELGKAIVKREGNSSQNWQRFYQLTK
LLDSMHEVVENLLNYCFQTFLDKTMSIEFPEMLAEIITNQIPKYSNGNIKKLLFHQK</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020486|Glucocorticoid receptor (NR3C1)
ATGGACTCCAAAGAATCATTAACTCCTGGTAGAGAAGAAAACCCCAGCAGTGTGCTTGCT
CAGGAGAGGGGAGATGTGATGGACTTCTATAAAACCCTAAGAGGAGGAGCTACTGTGAAG
GTTTCTGCGTCTTCACCCTCACTGGCTGTCGCTTCTCAATCAGACTCCAAGCAGCGAAGA
CTTTTGGTTGATTTTCCAAAAGGCTCAGTAAGCAATGCGCAGCAGCCAGATCTGTCCAAA
GCAGTTTCACTCTCAATGGGACTGTATATGGGAGAGACAGAAACAAAAGTGATGGGAAAT
GACCTGGGATTCCCACAGCAGGGCCAAATCAGCCTTTCCTCGGGGGAAACAGACTTAAAG
CTTTTGGAAGAAAGCATTGCAAACCTCAATAGGTCGACCAGTGTTCCAGAGAACCCCAAG
AGTTCAGCATCCACTGCTGTGTCTGCTGCCCCCACAGAGAAGGAGTTTCCAAAAACTCAC
TCTGATGTATCTTCAGAACAGCAACATTTGAAGGGCCAGACTGGCACCAACGGTGGCAAT
GTGAAATTGTATACCACAGACCAAAGCACCTTTGACATTTTGCAGGATTTGGAGTTTTCT
TCTGGGTCCCCAGGTAAAGAGACGAATGAGAGTCCTTGGAGATCAGACCTGTTGATAGAT
GAAAACTGTTTGCTTTCTCCTCTGGCGGGAGAAGACGATTCATTCCTTTTGGAAGGAAAC
TCGAATGAGGACTGCAAGCCTCTCATTTTACCGGACACTAAACCCAAAATTAAGGATAAT
GGAGATCTGGTTTTGTCAAGCCCCAGTAATGTAACACTGCCCCAAGTGAAAACAGAAAAA
GAAGATTTCATCGAACTCTGCACCCCTGGGGTAATTAAGCAAGAGAAACTGGGCACAGTT
TACTGTCAGGCAAGCTTTCCTGGAGCAAATATAATTGGTAATAAAATGTCTGCCATTTCT
GTTCATGGTGTGAGTACCTCTGGAGGACAGATGTACCACTATGACATGAATACAGCATCC
CTTTCTCAACAGCAGGATCAGAAGCCTATTTTTAATGTCATTCCACCAATTCCCGTTGGT
TCCGAAAATTGGAATAGGTGCCAAGGATCTGGAGATGACAACTTGACTTCTCTGGGGACT
CTGAACTTCCCTGGTCGAACAGTTTTTTCTAATGGCTATTCAAGCCCCAGCATGAGACCA
GATGTAAGCTCTCCTCCATCCAGCTCCTCAACAGCAACAACAGGACCACCTCCCAAACTC
TGCCTGGTGTGCTCTGATGAAGCTTCAGGATGTCATTATGGAGTCTTAACTTGTGGAAGC
TGTAAAGTTTTCTTCAAAAGAGCAGTGGAAGGACAGCACAATTACCTATGTGCTGGAAGG
AATGATTGCATCATCGATAAAATTCGAAGAAAAAACTGCCCAGCATGCCGCTATCGAAAA
TGTCTTCAGGCTGGAATGAACCTGGAAGCTCGAAAAACAAAGAAAAAAATAAAAGGAATT
CAGCAGGCCACTACAGGAGTCTCACAAGAAACCTCTGAAAATCCTGGTAACAAAACAATA
GTTCCTGCAACGTTACCACAACTCACCCCTACCCTGGTGTCACTGTTGGAGGTTATTGAA
CCTGAAGTGTTATATGCAGGATATGATAGCTCTGTTCCAGACTCAACTTGGAGGATCATG
ACTACGCTCAACATGTTAGGAGGGCGGCAAGTGATTGCAGCAGTGAAATGGGCAAAGGCA
ATACCAGGTTTCAGGAACTTACACCTGGATGACCAAATGACCCTACTGCAGTACTCCTGG
ATGTTTCTTATGGCATTTGCTCTGGGGTGGAGATCATATAGACAATCAAGTGCAAACCTG
CTGTGTTTTGCTCCTGATCTGATTATTAATGAGCAGAGAATGACTCTACCCTGCATGTAC
GACCAATGTAAACACATGCTGTATGTTTCCTCTGAGTTACACAGGCTTCAGGTATCTTAT
GAAGAGTATCTCTGTATGAAAACCTTACTGCTTCTCTCTTCAGTTCCTAAGGACGGTCTG
AAGAGCCAAGAGCTATTTGATGAAATTAGAATGACCTACATCAAAGAGCTAGGAAAAGCC
ATTGTCAAGAGGGAAGGAAACTCCAGCCAGAACTGGCAGCGGTTTTATCAACTGACAAAA
CTCTTGGATTCTATGCATGAAGTGGTTGAAAATCTCCTTAACTATTGCTTCCAAACATTT
TTGGATAAGACCATGAGTATTGAATTCCCCGAGATGTTAGCTGAAATCATCACCAATCAG
ATACCAAAATATTCAAATGGAAATATCAAAAAACTTCTGTTTCATCAAAAGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00104</identifier>
            <name>Hormone_recep</name>
          </pfam>
          <pfam>
            <identifier>PF00105</identifier>
            <name>zf-C4</name>
          </pfam>
          <pfam>
            <identifier>PF02155</identifier>
            <name>GCR</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial matrix</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>glucocorticoid receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>glucocorticoid-activated RNA polymerase II transcription factor binding transcription factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II core promoter proximal region sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hormone binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription factor activity, sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to steroid hormone stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chromatin modification</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription initiation from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription, DNA-templated</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="2">
      <id>BE0002638</id>
      <name>Cytochrome P450 3A4</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A35773</ref-id>
            <pubmed-id>27084892</pubmed-id>
            <citation>Cerny MA: Prevalence of Non-Cytochrome P450-Mediated Metabolism in Food and Drug Administration-Approved Oral and Intravenous Drugs: 2006-2015. Drug Metab Dispos. 2016 Aug;44(8):1246-52. doi: 10.1124/dmd.116.070763. Epub 2016 Apr 15.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="P08684" source="Swiss-Prot">
        <name>Cytochrome P450 3A4</name>
        <general-function>Vitamin d3 25-hydroxylase activity</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide (PubMed:11159812). Catalyzes 4-beta-hydroxylation of cholesterol. May catalyze 25-hydroxylation of cholesterol in vitro (PubMed:21576599).</specific-function>
        <gene-name>CYP3A4</gene-name>
        <locus>7q21.1</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions>2-22</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.25</theoretical-pi>
        <molecular-weight>57342.67</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2637</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP3A4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M18907</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1337</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08684</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP3A4_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1,8-cineole 2-exo-monooxygenase</synonym>
          <synonym>1.14.13.-</synonym>
          <synonym>Albendazole monooxygenase</synonym>
          <synonym>Albendazole sulfoxidase</synonym>
          <synonym>Cholesterol 25-hydroxylase</synonym>
          <synonym>CYP3A3</synonym>
          <synonym>CYPIIIA3</synonym>
          <synonym>CYPIIIA4</synonym>
          <synonym>Cytochrome P450 3A3</synonym>
          <synonym>Cytochrome P450 HLp</synonym>
          <synonym>Cytochrome P450 NF-25</synonym>
          <synonym>Cytochrome P450-PCN1</synonym>
          <synonym>Nifedipine oxidase</synonym>
          <synonym>Quinine 3-monooxygenase</synonym>
          <synonym>Taurochenodeoxycholate 6-alpha-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021936|Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021937|Cytochrome P450 3A4 (CYP3A4)
ATGGCTCTCATCCCAGACTTGGCCATGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG
CTCCTCTATCTATATGGAACCCATTCACATGGACTTTTTAAGAAGCTTGGAATTCCAGGG
CCCACACCTCTGCCTTTTTTGGGAAATATTTTGTCCTACCATAAGGGCTTTTGTATGTTT
GACATGGAATGTCATAAAAAGTATGGAAAAGTGTGGGGCTTTTATGATGGTCAACAGCCT
GTGCTGGCTATCACAGATCCTGACATGATCAAAACAGTGCTAGTGAAAGAATGTTATTCT
GTCTTCACAAACCGGAGGCCTTTTGGTCCAGTGGGATTTATGAAAAGTGCCATCTCTATA
GCTGAGGATGAAGAATGGAAGAGATTACGATCATTGCTGTCTCCAACCTTCACCAGTGGA
AAACTCAAGGAGATGGTCCCTATCATTGCCCAGTATGGAGATGTGTTGGTGAGAAATCTG
AGGCGGGAAGCAGAGACAGGCAAGCCTGTCACCTTGAAAGACGTCTTTGGGGCCTACAGC
ATGGATGTGATCACTAGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA
GACCCCTTTGTGGAAAACACCAAGAAGCTTTTAAGATTTGATTTTTTGGATCCATTCTTT
CTCTCAATAATCTTTCCATTCCTCATCCCAATTCTTGAAGTATTAAATATCTGTGTGTTT
CCAAGAGAAGTTACAAATTTTTTAAGAAAATCTGTAAAAAGGATGAAAGAAAGTCGCCTC
GAAGATACACAAAAGCACCGAGTGGATTTCCTTCAGCTGATGATTGACTCTCAGAATTCA
AAAGAAACTGAGTCCCACAAAGCTCTGTCCGATCTGGAGCTCGTGGCCCAATCAATTATC
TTTATTTTTGCTGGCTATGAAACCACGAGCAGTGTTCTCTCCTTCATTATGTATGAACTG
GCCACTCACCCTGATGTCCAGCAGAAACTGCAGGAGGAAATTGATGCAGTTTTACCCAAT
AAGGCACCACCCACCTATGATACTGTGCTACAGATGGAGTATCTTGACATGGTGGTGAAT
GAAACGCTCAGATTATTCCCAATTGCTATGAGACTTGAGAGGGTCTGCAAAAAAGATGTT
GAGATCAATGGGATGTTCATTCCCAAAGGGGTGGTGGTGATGATTCCAAGCTATGCTCTT
CACCGTGACCCAAAGTACTGGACAGAGCCTGAGAAGTTCCTCCCTGAAAGATTCAGCAAG
AAGAACAAGGACAACATAGATCCTTACATATACACACCCTTTGGAAGTGGACCCAGAAAC
TGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTTCAG
AACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCCTGAAATTAAGCTTAGGAGGA
CTTCTTCAACCAGAAAAACCCGTTGTTCTAAAGGTTGAGTCAAGGGATGGCACCGTAAGT
GGAGCCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>albendazole monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>caffeine oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>quinine 3-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>taurochenodeoxycholate 6alpha-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>testosterone 6-beta-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>vitamin D 24-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>vitamin D3 25-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alkaloid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>androgen metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcitriol biosynthetic process from calciol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterocycle metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vitamin D metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>